5-Minute Check In: Evaluating the Use of Resmetirom in Patients with NASH and Liver Fibrosis

5-Minute Clinical Update and Grand Rounds with Dr. Thomas McGinn

First-of-its-kind medication shows promise for liver disease patients

• Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is estimated to affect nearly one-quarter of adults in the United States. Nonalcoholic steatohepatitis (NASH) is a form of MASLD that can cause liver fibrosis, cirrhosis, liver failure, and liver cancer. It is one of the most common reasons why patients need liver transplants.
• The FDA recently granted accelerated approval to resmetirom, the first medication to treat nonalcoholic steatohepatitis (NASH) and liver fibrosis.
• Prior to the FDA approval, there were no approved drugs to treat this disease

In this 5-minute check in, we review the promising phase 3 data from a randomized trial that led to FDA approval including the results, the implications for patient care, and the potential to transform the landscape of NASH management

Guest: Dr. Justin Reynolds, Associate Professor, Creighton University School of Medicine, Gastroenterologist and Transplant Hepatologist, St Joseph's Hospital and Medical Center Transplant Center in Phoenix, Arizona.

Study: https://www.nejm.org/doi/10.1056/NEJMoa2309000